Qiagen Stock (NYSE:QGEN), Trade Ideas

Qiagen

Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Qiagen NV

Qiagen N.V.

TWST

Analyst Color

News

Upgrades

Price Target

Analyst Ratings

Trading Ideas

QGEN

Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division&#39;s gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing revenue and profit margins.

Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion

Equities

Mid Cap

Health Care

Markets

General

QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in 

Qiagen&#39;s Health Odyssey: Expanding In Riyadh And Partnering In Public Projects

Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics.

Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States. Together, QIAGEN and IPPA are committed to promoting the use of IGRA testing, such as QIAGEN's QuantiFERON-TB Plus, to ensure a safe immigration process and support the global fight against TB. IPPA is a U.S.-based non-profit organization of physicians who are authorized to conduct immigration medical evaluations by governments of countries that receive migrants, including the U.S., Australia, Canada, New Zealand and the United Kingdom.
"Our collaboration with IPPA enables us to raise awareness about the benefits of IGRA testing and support the U.S. national strategy to eliminate TB domestically by 2050. This partnership will lead to better detection of latent TB infection before departure for the United States and help identify immigrants who would benefit from preventive treatment," said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics business area at QIAGEN.
Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, "Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available. This partnership will play a crucial role in global efforts to combat TB."
The updated CDC guidelines now mandate that by October 1, 2024, all individuals aged above 2 years old from countries with a WHO-estimated TB incidence rate of more than 20 cases per 100,000 people will require an IGRA test as part of their U.S. immigrant visa medical exam, expanding from the previous requirement covering only children age 2 to 14.
Additionally, in anticipation of World TB Day, QIAGEN is hosting a global CPD-accredited event on March 21, 2024, with top TB experts discussing the vital theme of "TB infection screening and preventive therapy for achieving End TB strategy goals". The program will explore the global TB landscape, advances in testing and prevention, and screening of migrants. A panel discussion will address TB epidemiology, cost-effectiveness, and challenges faced by high-risk groups like migrants and children.
Tuberculosis is a contagious bacterial infection spread primarily by coughing of patients with the active pulmonary form of the disease. The WHO estimated that there were more than 10 million new cases of active TB worldwide and 1.3 million deaths in 2022. One in four people worldwide are believed to have latent TB infections, with 5-10% of them expected at some point to develop active TB. Screening for latent TB infection is therefore essential in the effort to end TB.
QIAGEN's QuantiFERON-TB Gold Plus assay accurately detects TB infection by identifying interferon-gamma released by T-cells in response to TB-specific antigens. This one-visit test outperforms the century‑old, two-visit TB skin test (TST), particularly for patients from high-TB-burden countries who have received BCG vaccination. The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus to combat the global TB epidemic.
For more information and to register for this event, please visit <a href="https://www.globenewswire.com/Tracker?data=8Uu_t7QBAHt-Slwt5iMVYNfX13gzxzFqB0mLh1ybiiw73432d1lfeQe-R7aNSeZXeLM1ZBBaCBINTyz6uJaGGTAf2lD-um7O5JQiciVNWyrxwAhv5f1hLQ1Z-Cn16dqbXwPfY6GaKK5tw3z-nhc4tXatCx-c_zggKRnGvYUUQUzLy9Rw7OgUXpje3D11TycVfYmzxclKPXNo5mnv6FBXUnoFzfl4A97ligDXpptdkrQ=">https://www.qiagen.com/us/applications/tb-management/events/world-tb-day</a>

Biotech

QIAGEN Partners With International Panel Physicians Association To Increase Awareness Of Tuberculosis Screening Requirements

QIAGEN Unveils AI-Derived Biomedical Knowledge Base To Accelerate Data-driven Drug Discovery

JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Overweight and raises the price target from $50 to $52.

JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $52

Citigroup analyst Patrick Donnelly maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Buy and lowers the price target from $61.86 to $60.

Citigroup Maintains Buy on Qiagen, Lowers Price Target to $60

For 2024, QIAGEN has set an outlook for net sales of at least $2.0 billion CER. This reflects full-year total growth of at least 2% CER, with solid mid-single-digit CER sales growth in H2 2024 in the non‑COVID portfolio over the year-ago period. This outlook also includes about one percentage point of COVID-19 sales headwinds from 2023. Consumables and related revenues are expected to drive growth, while larger-scale instrument sales remain challenging. QIAGEN also continues to closely monitor dynamic geopolitical and macro trends around the world. Adjusted diluted EPS are expected to be at least $2.10 CER. This reflects at least one percentage point of improvement in the adjusted operating income margin to above 28% for FY 2024 compared to 2023 while supporting investments in the portfolio, in particular to accelerate growth in the QIAGEN Digital Insights bioinformatics business. Significant pressure is expected on non-operating income for FY 2024 due to anticipated lower interest income and a higher tax rate compared to 2023, more than offsetting benefits from the recently completed $300 million synthetic share repurchase.

Guidance

QIAGEN Sees FY24 EPS $2.10 CER Vs $2.20 CER Est.; Revenue Of At Least $2B CER Vs 2.06B CER Est.

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.53 by 3.77 percent. This is a 3.77 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $503.00 million which beat the analyst consensus estimate of $501.28 million by 0.34 percent. This is a 1.01 percent increase over sales of $497.98 million the same period last year.

Earnings

Earnings Beats

Qiagen Q4 EPS $0.55 Beats $0.53 Estimate, Sales $503.00M Beat $501.28M Estimate

Rumors

Watching Qiagen N.V.; Traders Circulating Stock May Be Seeing Interest Amid Takeover Chatter

AEIS

AGCO

AMCR

AMGN

AMRK

AOSL

ARCB

ARMK

ARWR

ASTL

ATEN

ATHM

AUDC

AVNW

AZEK

AZPN

CARR

CEIX

CHKP

CINF

CRNC

CRUS

CTSH

DCPH

DIOD

ENPH

EXEL

FRSH

FTNT

GAIN

GEHC

GILD

HIMX

HLNE

ICHR

INGR

INNV

INSP

INTA

JKHY

KREF

KTCC

LPTV

LSAK

LUMN

MODN

MRCY

MSGS

MSTR

PLUS

Earnings Scheduled For February 6, 2024

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-06. Here's what investors need to know before the announcement.
Analysts estimate that Qiagen will report an earnings per share (EPS) of $0.53. 
Qiagen bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 5.29% increase in the share price the next day.
Here's a look at Qiagen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.48</td>
<td>0.50</td>
<td>0.47</td>
<td>0.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.51</td>
<td>0.51</td>
<td>0.53</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.29%</td>
<td>0.31%</td>
<td>2.45%</td>
<td>-0.86%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707145339_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Qiagen were trading at $43.51 as of February 02. Over the last 52-week period, shares are down 16.63%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/QGEN/earnings">To track all earnings releases for Qiagen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Qiagen

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, which involves the research into a community of microorganisms that can be found living together in any given environment, including the human body.
In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center. It is also designed to provide vital industry research and training opportunities for next-generation scientists. This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.
"This new partnership with Penn State, one of the leading academic research institutions in the field of microbiome research, is anchored by a shared vision for an interconnection between the health of humans, animals and ecosystems. It will help shape research, education and outreach in the young field of the microbiome sciences, and hopefully accelerate the careers of a new generation of scientists interested in this field," said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN. "Additionally, it will foster relationships with the microbiome research community and enable us to better develop new products for microbiome research based on direct customer feedback."
Seth Bordenstein, Director of the One Health Microbiome Center, Professor of Biology and Entomology, and Huck Endowed Chair in the Microbiome Sciences, at Penn State said: "The ‘One Health' vision shared by QIAGEN and Penn State University is critical for microbiome research. We are pleased to partner with the leading provider of microbiome solutions to equip researchers with the tools to explore how microorganisms flow through humans, animals, plants and the environment, impacting the health of all these ecosystems. With this multi-year partnership, we will bridge the gap between industry and academia and shape the future of microbiome research."
Among the various projects in this partnership, the team will support the worldwide science education program "Discover the Microbes Within! <a href="https://www.globenewswire.com/Tracker?data=Z42m9jheaeUEcCwFPnfm3dPiFq_xexQ7y9lanXNpGfDWBsT_gyI8SbsrQ7G0LF9l2ul1ni4IZX98WNUzCoxufpni4JNyGA7Sh2p6EHHr8IY=">The Wolbachia Project</a>". This program enables students at the middle and high school levels, as well as those in college, to learn about arthropods (animals without backbones that have an outer skeleton made of chitin, segmented bodies and legs with joints, including insects, spiders, mites and crustaceans) and collect scientific data about the bacterial endosymbiont (an organism living inside another one for the benefit of both) Wolbachia pipientis.
This bacterium is estimated to be found in approximately 50% of the world's arthropods and has been shown, for example, to block the reproduction of potentially fatal RNA viruses such as Dengue, West Nile and Zika virus<a href="https://www.globenewswire.com/Tracker?data=x9dofGyfZHn_cv0R9deazQwjkjRMcj-k4vz5vmy6HiYc49xkaTyfzgnzpDLVZzpP">[1]</a>. Additionally, it is used to reduce the transmission of these and other viruses spread by the bite of infected arthropods (arboviruses)<a href="https://www.globenewswire.com/Tracker?data=JyKqJNtlyPKPq94SCgfMOx-n8oKotre4o7VKhoWtzijJnK2CQIcwTp_gy76hzkOO">[2]</a>. Due to these real-world impacts, Wolbachia is often used as a model organism to investigate animal-microbe interactions, genetics, evolution, ecology and human health.
Microbiome research aims to explore the relationships between microorganisms such as bacteria, fungi and viruses, and their hosts. It can help to better understand the microbiome's impact on health, diseases and ecological processes in order to develop novel diagnostic solutions and therapeutic strategies.
The flagship project at the <a href="https://www.globenewswire.com/Tracker?data=pqQ4oSbVqTK7cVkbfHOqxIL9mVtbZBdG6BIMGWwu0p6Ek_dr09IF5A4Hx-xF2A5UOt5_4Fx_mhBmrMKvlmubgSM2pyva30J1tsoaaTjG4vNcWiWlP0_Ii55x67iaofFllb6QDTzJZQupgwHPLNP_WrpqngYnNg5mpwxj7tWQ1is=">One Health Microbiome Center (OHMC)</a> at Penn State's Huck Institutes of the Life Sciences will see QIAGEN provide instruments and kits for preparing and processing microbial samples.
Penn State is among the top 30 public research universities in the U.S., with more than $1.2 billion in annual research expenditures. With over 500 members, including 125 faculty from various Penn State campuses and more than 42 departments, OHMC is one of the largest organizations of its type in microbiome research.
QIAGEN's comprehensive microbiome portfolio encompasses tools for every aspect of the scientific workflow, including reliable sample preparation kits optimized for investigating challenging samples from environmental and human microbiomes. To ensure reproducibility, QIAGEN offers sample preparation automation for standardization and reliability. The extensive range of microbiome solutions also includes downstream processing technologies such as NGS, digital PCR (dPCR), or quantitative PCR (qPCR), all complemented by robust bioinformatics tools for seamless digital analysis.
Learn more about QIAGEN's solutions for microbiome research at <a href="https://www.globenewswire.com/Tracker?data=QAhlPokmAoikFQfAc4ty2sTCT0xOB7vDRW7Jvo6R1X9oRaE_kz7iyiErGyhSH5fvy1EWrsJcN4mZdNZNkuMNGqBvR0NcRMHjHHARJwdGKR_F1psprLiDvXtuILkFAsVbiRt0TsS0UtFtIKb95nT8QNcudaNi6EnGoA6Fk2ScnwE=">https://www.qiagen.com/us/applications/microbiome</a>.

QIAGEN Announces Partnership With Penn State University To Advance Microbiome Sciences

Goldman Sachs&nbsp;has upgraded&nbsp;Twist Bioscience Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) looking forward to 2024 and beyond, and the analyst sees the critical new product launch of Express Genes directly addressing their gross margin issues within their SynBio division.&nbsp;
Historically, well-funded larger biopharma companies were challenging for TWST to penetrate due to extended gene delivery timelines.&nbsp;
However, with the introduction of Express Genes for new customers in 2024, TWST can now cater to these companies by delivering genes within 5-7 days, positioning Twist to tap into a previously inaccessible market and offering a unique growth opportunity to enhance revenue and profit margins.
Goldman analyst has upgraded the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/TWST/analyst-ratings" rel="noreferrer noopener">stock from Neutral to Buy</a>.
The expedited delivery of Express Genes mitigates the risk associated with recovery timing for smaller biotech funding, providing a strategic advantage for TWST.
The market views the next-generation sequencing Tools business favorably, appreciating its consistent growth in recent years, competitive standing against peers such as&nbsp;Agilent Technologies Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) and&nbsp;Qiagen NV&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>), and favorable gross margin performance.&nbsp;
However, there is significant debate surrounding the SynBio division, primarily due to its struggle to achieve satisfactory gross margins.&nbsp;
This challenge is attributed to a low-priced strategy and difficulty tapping into the lucrative gene makers market, estimated at $1.4 billion Total Addressable Market, according to Twist.
Due to the adverse impact of high interest rates and inflated valuations in 2020-2021, there was a significant decrease in venture capital funding for the biotech sector in the past year.&nbsp;
This led to a re-evaluation of project priorities and a lower demand for synthetic biology (SynBio) products in the biotech market in 2023. Despite challenges in predicting the exact timing of a recovery in small-cap biotech funding, there are early indications of a positive trend in biotech funding. 
While it&#8217;s uncertain if this marks the bottom, Twist is expected to benefit significantly if a turnaround becomes evident.
Price Action:&nbsp;TWST shares are down 1.62% at $34.70 on the last check Wednesday.

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States.
This assay is designed for direct detection of asymptomatic and symptomatic bacterial infections involving&nbsp;Chlamydia trachomatis&nbsp;(CT) and / or&nbsp;Neisseria gonorrhoeae&nbsp;(NG) &ndash; the most common type of bacterial infection among sexually transmitted infections (STIs), according to the U.S. National Institutes of Health. The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics. However, the time it takes for results to be received is often long, impeding follow-up care.
This FDA clearance supports the test menu expansion for NeuMoDx Molecular Systems in the U.S. It also builds on the 16 EU-certified in-vitro diagnostics (CE-IVD) tests available on these systems, which is one of the broadest on the market in countries accepting CE-IVD markings, including assays for transplant-associated viruses, respiratory infections, blood-borne viruses, and sexual and reproductive health.

Government

Regulations

QIAGEN Bags FDA Clearance of NeuMoDx CT/NG Assay for Both NeuMoDx 96 and 288 Molecular Systems

QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR&nbsp;273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split.
QIAGEN has decided to implement the maximum $300 million value of the mandate given at the Annual General Meeting in June&nbsp;2023, where shareholders gave virtually unanimous approval for the related resolutions. This approach is designed to return cash to shareholders in a more efficient way than through a traditional open-market repurchase program. It would also enhance earnings per share (EPS) through the reduction in outstanding shares. The synthetic share repurchase will become effective on January 29, 2024, and will be settled in line with market convention in the subsequent days.
This type of synthetic share repurchase involves the following three general steps:
<ol>
<li>The par value of QIAGEN&rsquo;s common shares (EUR&nbsp;0.01 per share) will be increased through a transfer from the Share Premium Reserve (included in &ldquo;Additional Paid-in Capital&rdquo; on the Company&rsquo;s balance sheet) to allow for the capital repayment to shareholders.</li>
</ol>
<ol>
<li>A reverse stock split will consolidate shares.</li>
</ol>
<ol>
<li>The par value will be reduced back to the original level of EUR&nbsp;0.01 per share and the capital repayment will be paid out directly to shareholders (as of the record date, and where applicable after conversion into U.S. dollars).</li>
</ol>
Further information on this process will be announced before implementation.

Buybacks

QIAGEN To Return ~$300M To Shareholders Through A Synthetic Share Repurchase

QIAGEN Announces Plan To Increase Investments In Its QIAGEN Digital Insights Business Over The Next Five Years

QIAGEN N.V.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>) disclosed its expansion plan in&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/24/01/g36463896/qiagen-expands-business-in-middle-east-with-new-regional-headquarters-and-major-projects" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">the Middle East region</a>.
The company plans to open its regional headquarters in Riyadh, Saudi Arabia, in early 2024 to boost its regional commercial footprint.
Also, QGEN recently penned a memorandum of understanding (MoU) with the Ministry of Health of Saudi Arabia, handling various public health and infection control initiatives.
The MoU comprises setting up a localized data center by QIAGEN Digital Insights (QDI) to support advanced bioinformatics within the country and assisting the Ministry in eliminating meningitis through its syndromic testing platform QIAstat-Dx.
The MoU also comprises developing a national latent TB screening program using QuantiFERON-TB Gold Plus and implementing a prevention screening program for cervical cancer under the WHO elimination initiative by 2030.&nbsp;
Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, said, &quot;At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.&quot;&nbsp;
In addition, QIAGEN has been awarded a tender through its Commercial Partner Taiba Medserv LLC from the Ministry of Health of the Sultanate of Oman to provide the country with QuantiFERON-TB Gold Plus tests for its nationwide tuberculosis (TB) screening program.
Also Read:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36137049/qiagen-has-steady-income-and-defensive-growth-potential-goldman-sachs-upgrades-stoc" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock</a>
In October, QGEN reported Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023, above the outlook for at least $465 million CER, driven by 5% CER growth in the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35512285/diagnostic-firm-qiagens-q3-earnings-analyst-says-annual-projections-attainable-desp" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">non-COVID-19 portfolio</a>.&nbsp;&nbsp;
Price Action: QGEN shares closed higher by 0.51% at $43.65 on Tuesday.

Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects

QIAGEN Bolsters Middle East Presence, Launches New Regional Headquarters And Undertakes Significant Projects

JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Overweight and raises the price target from $45 to $50.

JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $50

Wells Fargo analyst Timothy Daley initiates coverage on Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Equal-Weight rating and announces Price Target of $44.

Initiation

Wells Fargo Initiates Coverage On Qiagen with Equal-Weight Rating, Announces Price Target of $44

Wolfe Research analyst Doug Schenkel initiates coverage on Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Qiagen with Peer Perform Rating

Qiagen NV&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>) has a steady income from selling tools for preparing samples and diagnostics. This kind of business tends to stay strong even when companies aren&#39;t spending&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35512285/diagnostic-firm-qiagens-q3-earnings-analyst-says-annual-projections-attainable-desp" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">much on big equipment</a>.&nbsp;
The Dutch life science stock is currently the cheapest name in the Goldman Sachs Tools coverage universe, trading at 13.3x&#39; 24E EV/EBITDA vs. the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">sector</a>&nbsp;at 16.5x despite growing core organic growth in the high single-digit to low double-digit range over the past year.&nbsp;
The analyst expects these defensive characteristics to drive better than sector average growth in 2024.&nbsp;
Hence, Goldman Sachs upgrades Qiagen from Neutral to Buy to reflect the defensiveness of their end markets and&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/quote/QGEN/analyst-ratings" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">favorable valuation vs. peers</a>.
QGEN is trading at a &gt;5x discount to the rest of the Tools&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">sector</a>&nbsp;despite their revenue stream being more defensive in an uncertain environment, providing more visibility around 2025/2026 estimates.
QGEN&#39;s end market exposure positions them well in the current environment compared to the other Mature Tools names, given their defensive nature and the uncertainty in both timing and magnitude of Pharma demand normalization.&nbsp;
Their Life Sciences product portfolio is not a large portion of customer budgets, protecting them from downturns in the Pharma R&amp;D and Capex spending.
Price Action:&nbsp;QGEN shares are up 0.95% at $41.84 on the last check Thursday.

In a report released today, John Sourbeer from UBS maintained a Hold rating on Qiagen (QGEN – Research Report). The company's shares closed yesterd...

UBS Sticks to Their Hold Rating for Qiagen (QGEN)

Qiagen NV (QGEN) is up 0.41% today. QGEN has an Overall Score of 35. Find out what this means to you and get the rest of the rankings on QGEN!See Full QGEN ReportQGEN stock closed at $43.99 and is up $0.18 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors on

Qiagen NV (QGEN) Up 0.41% in Premarket Trading

Bio-Techne and Qiagen had the biggest increase in short interest levels last month - Baird

Qiagen NV (QGEN) stock is down -7.22% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives QGEN stock a score of  34 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 34. QGEN's rank also includes a

Is Qiagen NV (QGEN) Stock a Good Value?

Revvity: Enter Now As Reorganization Takes Shape

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen (QGEN – Research Report). The company's shares cl...

Deutsche Bank Remains a Buy on Qiagen (QGEN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report), Innate Pharma SA (IPHYF – Resear...

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Qiagen (QGEN – Research Report) today. The company's shares opened tod...

Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)

AVTR

BRKR

CSTL

CTKB

EXAS

ILMN

IPHYF

MRVI

NMRA

NTRA

RVTY

TCGGY

TCHBF

TECH

Press Releases

QIAGEN announces partnership with Penn State University to advance microbiome sciences

QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

QIAGEN announces Form 20-F annual report filing for 2023 results

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024